RayVa Topical Treatment Safe and Effective in Phase 2a SCL-Related Raynaud’s Phenomenon Trial from Apricus

Author: Maureen Newman
Date Published: September-2015
Source: Scleroderma News

Top-line results from the Apricus Biosciences, Inc. Phase 2a clinical trial for RayVa™ topical treatment in patients with scleroderma-related Raynaud’s phenomenon indicate the treatment is safe and effective. Patients tolerated treatment and reported a noticeable change in the way their skin temperature responded to a cold challenge. There are now plans to advance to a later stage Phase 2 clinical trial in 2016.